[{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"12","companyTruncated":"KVK.Tech \/ Medix"}]

Find Clinical Drug Pipeline Developments & Deals for Phentermine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.

                          Brand Name : Lomaira

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 31, 2024

                          Lead Product(s) : Phentermine Hydrochloride

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Medix

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank